Hannah Went on the future of health diagnostics and a brand-new app that could prove to be a healthspan gamechanger.
Just two weeks away, Founders Longevity Forum Singapore will serve as a key platform for driving discussions on how science, policy and investment can converge to accelerate progress in longevity. With the global population aging, the need to transition healthcare from reactive treatment to proactive prevention has never been more urgent. This shift relies on cutting-edge diagnostics and therapeutics that extend healthspan and reduce the burden of age-related diseases – an area FLF:SG will explore in depth.
Bringing together leading experts, researchers and industry pioneers, FLF:SG will highlight advancements in epigenetics, biomarker testing and precision diagnostics that enable earlier interventions and improve clinical adoption. By fostering collaboration, the forum aims to make longevity-focused healthcare more accessible, bridging the gap between scientific innovation and real-world impact.
TruDiagnostic is at the forefront of longevity science, specializing in DNA methylation-based diagnostics that provide deeper insights into biological aging. With over 75,000 patients tested and more than 30 approved clinical trials, the company is helping to define the role of epigenetics in preventive healthcare. By equipping clinicians and consumers with precision aging biomarkers, TruDiagnostic is bridging the gap between research and real-world applications in longevity and health optimization.
Longevity.Technology: At FLF:SG, TruDiagnostic Cofounder and Director of Operations Hannah Went will be driving the conversation on the clinical and consumer adoption of biological age testing. In her session on the Use of Biological Gerodiagnostics in Clinical Settings, she’ll be exploring how epigenetic data can enhance personalized medicine and longevity-focused interventions. In Consumer Diagnostics for Longevity and Healthspan, she will be discussing the growing accessibility of biological aging tests and their role in empowering individuals to take control of their long-term health. Through TruDiagnostic’s research and innovation, Went is helping shape the future of longevity-focused diagnostics, and ahead of the Forum, we sat down with her to discuss the integration of AI in diagnostics, the role of epigenetics as a promising biomarker and advancements in longevity diagnostics.
Hannah Went on…
Measuring up
Symphony Age is super unique because it talks about the heterogeneity of our organ systems. As humans, we don’t all get liver disease or heart disease or dementia, Alzheimer’s at the same age, so we know our organs tick at a different rate. We’re able to actually look at 11 of them together – it’s really groundbreaking work because it gets us closer and closer to that precision-based medicine; actually being able to say a brain is aging a little bit faster and consider how can we look at biomarkers which make up the brain age, attack them directly and start to lower the brain age and make it younger to reduce risk of mortality as well as morbidities associated with that specific organ function.
Epigenetics is the future
I’m excited to be talking about at Founders Longevity Forum as I’ll be debuting some of our newer research. TruDiagnostic is very different because we’re only looking at epigenetics as a biomarker. We believe epigenetics is the future of medical diagnostics because it gives us the ability to create simple, affordable at-home tests with just a few drops of blood. Our tests can accurately diagnose multiple – and this is a big statement here – but multiple chronic diseases affecting 3 billion people worldwide, potentially saving tens of thousands of dollars from that user. We’re actually able to now report on about 1,600 of those epigenetic biomarkers that perform better than their traditional versions – again, normally costing tens of thousands of dollars. This one biomarker we’re using in particular – epigenetics – has just been seen to really blow all the other biomarkers out of the water.
One app to rule them all
Our bioinformatics team are incorporating machine learning and artificial intelligence into the epigenetic clock models, and we see this as more of a preventative medicine approach. We will be able to help both patients and clinicians alike through a development of an app that we’re creating at the moment. We’ll be using some language modeling to actually be able to take all of those biomarkers in one place and start to be able to give you recommendations based on those biomarkers – and that’s integrating everything. So it doesn’t just have to be epigenetics, although that’s where it will probably be started, but you can feed it your genetic data, you can feed it your wearable data, and it’s going to be able to reply and really know you better than maybe even your clinician one day.
We hope to bring that app out this year, maybe even around Q2 – we’re trying to get a beta version out as quickly as possible. It is going to make healthcare really accessible; this more front-facing, longevity-based healthcare will be more accessible – really in your back pocket.
Looking forward to Singapore
I’m really going to be talking about just epigenetic biomarkers in general. TruDiagnostic has the age testing, and we have just released a new product called True Health, which is looking at about 110 different antioxidants, vitamins, nutrition markers, other health systems and condition markers. I’ll be discussing how epigenetics is able to actually report out on chronic disease state, too, but first I will take it back to basics, defining just what a biomarker is and why we think epigenetics looks to be the best biomarker.
It really comes down to three things. Number one, the predictive power of that biomarker – how much does it increase or decrease the odds of having or developing a disease? Number two, the reliability and precision of that biomarker – can we actually trust what it’s telling us? And then number three, the ease of collection – basically everything logistics wise, such as the cost, the complications, how easy is it to perform? And when you line up all of these markers interpreted from epigenetics, we do think they actually prove out to be better compared to their traditional counterparts. And that’s really what I’m going to drive home!
Register your interest to participate at Founders Longevity Forum Singapore.
